FIELD: biotechnologies.
SUBSTANCE: invention relates to biotechnology and can be used in medicine. Invention discloses novel antisense oligonucleotides containing at least one modified nucleotide from oligonucleotides SEQ ID NO: 1-3 and capable of effectively inhibiting expression of protein TGF-β2. Antisense oligonucleotides according to present invention can be used in therapy of diseases associated with pathological expression of TGF-β2, including various types of cancer.
EFFECT: antisense oligonucleotides according to the present invention have improved stability in plasma in comparison with oligonucleotides containing no modifications.
10 cl, 21 dwg, 15 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOUBLE-CHAINED OLIGONUCLEOTIDE SPECIFIC TO CTGF GENE AND COMPOSITION CONTAINING IT FOR PREVENTION AND TREATMENT OF FIBROUS DISEASES AND DISEASES ASSOCIATED WITH RESPIRATORY SYSTEM | 2020 |
|
RU2807108C1 |
| ANTISENSE OLIGONUCLEOTIDES TARGETING CAV3.1 GENE AND USES THEREOF | 2022 |
|
RU2839721C2 |
| NEW OLIGONUCLEOTIDES CONJUGATES AND USE THEREOF | 2012 |
|
RU2599449C1 |
| AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDES AND COMPOSITIONS CONTAINING THEM FOR THE PREVENTION AND TREATMENT OF FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES | 2019 |
|
RU2795179C2 |
| COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASE ASSOCIATED WITH OBESITY, CONTAINING AMPHIREGULIN-SPECIFIC DOUBLE-CHAIN OLIGONUCLEOTIDE STRUCTURE | 2021 |
|
RU2810514C1 |
| ANTISENSE OLIGONUCLEOTIDES AS INHIBITORS OF SIGNAL PATH TGF-R | 2015 |
|
RU2717454C2 |
| ANTISENSE TYROSINASE OLIGONUCLEOTIDES | 2018 |
|
RU2778786C2 |
| DEEP GLYCATION END PRODUCTS RECEPTOR MODULATORS AND MODULATION | 2020 |
|
RU2820247C2 |
| CANCER IMMUNOTHERAPY | 2014 |
|
RU2744194C2 |
| MODULATION OF HUNTINGTIN EXPRESSION | 2010 |
|
RU2562861C2 |
